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Abstract: Nowadays, regenerative medicine has paid special attention to research (in vitro and
in vivo) related to bone regeneration, specifically in the treatment of bone fractures or skeletal
defects, which is rising worldwide and is continually demanding new developments in the use
of stem cells, growth factors, membranes and scaffolds based on novel nanomaterials, and their
applications in patients by using advanced tools from molecular biology and tissue engineering.
Strontium (Sr) is an element that has been investigated in recent years for its participation in the
process of remodeling and bone formation. Based on these antecedents, this is a review about the
Strontium Folate (SrFO), a recently developed non-protein based bone-promoting agent with interest
in medical and pharmaceutical fields due to its improved features in comparison to current therapies
for bone diseases.
Keywords: bone regeneration; musculoskeletal defects; strontium folate
1. Introduction
The rise in the average age of the population has led to a steady increase in the number of
musculoskeletal conditions and in particular of cartilage and bone surgical procedures in the last
years [1,2]. Therefore, the development of alternative materials and strategies in bone replacement
therapies has attracted high interest. Above a critical size, bone defects are not repaired by the
self-healing system of the tissue; thus, an osteoconductive and osteoinductive device (or scaffold) is
usually required in order to regenerate the lost tissue. The scaffold must be composed of materials that
stimulate and favor the formation of new bone tissue as well as to be structurally stable during the
process of cell growth and expansion [3]. In this regard, autografts are still amply considered as the
“gold standard”; however, they have many drawbacks such as limited availability and morbidity of
the donor site [4,5]. Alternatively, a proper scaffold made of a given biomaterial would be desirable
both to fill the defect and to act as a reservoir for growth factors and/or cells [6,7].
High biocompatibility and proper physical-chemistry of the surface are the most essential
requirements in biomaterials intended to be used in scaffold construction [6,7]. Nonetheless, several
others important criteria must also be taken into account; these are cell adhesion, proliferation and
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differentiation, biodegradability, mechanical efficiency (in a given specific application), bio-conductivity,
bioactivity, suitability to the sterilizing procedure, stability during storage, and finally, high
cost-effectiveness ratio [6,7]. Polymers are usually good candidates despite only few are those
displaying most of the characteristics required for their use as bone substitutes [8]. Additionally, some
polymers may generate inflammation (an immunological reaction to foreign body). Such reaction
usually leads to the failure of the engineered product, and thus severely restricting the use of these
polymers as scaffolds [9]. To date, unfortunately, there are no materials with the desired characteristics
to construct an optimal scaffold, i.e., with the properties required to generate new bone tissue [10].
Currently, the employment of different types of technologies as well as the generation of new polymeric
synthetic scaffolds has become an attractive option in order to overcome the drawbacks of synthetic
and natural polymers [11]. Furthermore, the inclusion of metal ions and trace elements essential in
bone formation may be considered in scaffold synthesis, e.g., calcium (Ca2+), magnesium (Mg2+), and
phosphate ions (PO43−), while metallic trace elements when incorporated into bone structure promote
both osteogenesis and angiogenesis thus enhancing bone remodeling and the repair process [12].
Notably, amongst the metallic trace elements, Sr has been extensively studied [10]. Sr, because of its
resemblance (in charge and size) to calcium (Ca), has the ability to substitute Ca ions in the apatite
structure [10,13]. Jimenez et al. reported that Sr induces human stem cell differentiation towards
cartilage and bone like phenotypes in vitro. Thus, biomaterials containing Sr would enhanced their
performance both in vitro and in vivo, that is, by inducing the formation of new bone and cartilage
tissues while inhibiting tissue resorption [14].
Certainly, Sr stimulates the activity of osteoblasts while inhibiting the activity of osteoclasts [14]. In
this regard, Place et al. evaluated the osteogenic potential and showed that Sr may improve osteogenic
differentiation [15]. Accordingly, some authors performed the transplantation of strontium-based
systems in bone defects [16,17]; computed tomography and histological analysis showed a significant
improvement in bone formation in vivo, i.e., the amount of both mature and remodeled bone
substantially increased and extracellular matrix accumulated [16,17]. Further studies showed that Sr
increased the expression of β-catenin in the newly formed bone, and such an effect was expected to
occur either in vitro and in vivo, e.g., a significant osteogenic differentiation of mesenchymal stem
cells (MSCs) was expected when in the presence of Sr, and consequently, the formation of bone [15–18].
Additional studies suggested the incorporation of Sr ions in bone substitutes but were also shown to
be effective in the stimulation of the proliferation and differentiation of bone MSCs, osteoblasts, and
periodontal ligament cells in vivo [19–21]. Hence, a three-dimensional (3D) biohybrid scaffold based
on calcium phosphate and a bio-active derivative of Vitamin-B and Sr (Strontium Folate, SrFO) was
developed. This device induced the healing of critical-sized cranial defects in rats using human dental
pulp stem cells (HDPSCs) without the addition of exogenous growth factors. The seeded HDPSCs
proliferated and differentiated, hence developing a bone regenerative capacity. This seems to be a
novel tissue engineering approach to regenerate critical sized bone defects in vivo [16]. Due to the
high potential of SrFO in bone regenerative medicine, currently, new regenerative devices have been
developed based on SrFO. Very recently, Xu et al. demonstrated that strontium folic acid derivatives
promote in vitro the osteogenic differentiation of MSCs shortly after addition; especially in the long
term. Particularly, such derivatives improved significantly bone formation around the bio-functional
orthopedic implants in vivo, which was highly evident at late stages [17].
2. Factors Involved in the Repair of Bone Tissue
The process of bone tissue repair involves a complex cascade of biological events controlled by
numerous cytokines and growth factors (GF). These factors provide the signals that induce the migration
of osteoprogenitor cells and promote the subsequent differentiation and proliferation in cell lineages,
tissue revascularization, and production of the extracellular matrix [22]. Therefore, the inclusion of
growth factors, as well as bone morphogenetic proteins (BMPs), and fibroblastic growth factors (FGFs)
in scaffolds seeded with stem cells have been demonstrated to be important in the effectiveness of the
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regenerative process [23]. However the use of these GF in clinical applications has been restricted due
to their limited availability in terms of price, shelf life during storage and manipulation, and the short
time in effectiveness after their application due to hydrolysis, neutralization, and degradation.
Bone tissue consists mainly of the protein collagen (~90%), and of cells with a role in bone
formation and growth, repair and synthesis of the extra cellular matrix [23,24]. The matrix is formed
by a small binding integrin-linked to glycoprotein N. The sibiling protein family is formed by five
members: (a) osteopontin (OPN), (b) fosfoglycoprotein of the extracellular matrix (MEPE), (c) bone
sialoprotein (BSP), (d) dentin matrix protein 1 (DMP1), and (e) dentin sialophosphoroprotein (DSPP).
The members of the family share some structural characteristics, namely: collagen binding domain,
HA binding domain, and arginine-glycine-aspartic acid (RGD) cell binding domain [23]. Undoubtedly,
these proteins have an important role in bone development, i.e., facilitating cell adhesion, nucleation,
and mineral maturation. Nonetheless, researchers are still trying to elucidate the exact role of each
protein in natural bone development [24,25].
Tumor necrosis factor α (TNFα) is one of the most potent osteoclastogenic cytokines. TNFα
stimulates bone resorption in vitro and in vivo by increasing the proliferation and differentiation
of osteoclast precursors [26,27]. In contrast, OPG can reverse the loss of bone in animal models
of sex-steroid insufficiency and glucocorticoid-induced osteoporosis, rheumatoid arthritis, multiple
myeloma, and metastatic bone disease [28]. Since OPG directly counteracts all RANKL mediated
activities through RANK, therefore the RANKL/OPG ratio is determinant in bone mass and integrity
of the skeleton. In contrast, the increased expression of RANKL by tumor cells and tumor-mediated
increase of RANKL/OPG ratio in bone microenvironment may be observed in myelomas and in
osteolytic metastasis in prostate and breast cancer [27,29–33].
3. Dental Pulp Stem Cells and Osteogenic Differentiation
Stem cells are generally defined as clonogenic cells capable of self-renewal; these are
non-specialized cells that renew by cell division with the remarkable ability to differentiate to a
specific cellular type [34–36]. Since stem cells are able to repair or replace damaged tissues, thus leading
to recover from illness (or injury), they have been employed successfully. Therefore, the number
of patients subjected to tissue transplants, plus patient receptors of stem cell therapy, has increased
recently [11].
Dental pulp has been considered an excellent source of adult stem cells, even better than bone
marrow. Hence, research has been focused to test its therapeutic application [3,37], e.g., in tissue
engineering, where numerous laboratories have assessed its potential in pre-clinical applications in
the regeneration of tissues [33]. Importantly, adult dental pulp tissue does contain multipotential
stem cells and under given conditions, the derived pulp stem cell cultures may develop to specialized
odontoblasts-like cells competent to form mineralized nodules in vitro [34]. In this regard, dental tissues
are easily accessible during routine clinical practice, namely upon tooth extraction; thus providing a
source of trustworthy stem cells, ideal for development and testing of new therapies [38]. Technically,
stem cells are isolated from pulp tissues degraded from the selection of a unique colony (Figure 1).
These stems cells usually exhibit high proliferation and clonogenic properties; they also exhibit the
typical immuno-reactivity profile of bone marrow stromal cells [34]. Furthermore, the osteogenic
cultures are able to synthesize fibers, similar to bone tissue, thus forming a densely mineralized matrix.
These so generated lamellar fibrous bone tissue usually tend to contain osteocytes, after transplantation
into living organisms [39].
Studies in engineering bone tissue have demonstrated the potential of DPSCs when in combination
with a 3D matrix. Mineralization and hard tissue formation are achieved by partially developed
hematopoietic bone tissue [40]. Similar results have been obtained upon implantation of manufactured
constructs consisted of DPSCs embedded in scaffolds [16,41]. It is worth to note that this strategy
produces a highly mineralized tissue. Thus, generating a deep interest and encouraging the use of
DPSCs in clinical bone tissue replacement therapies [41].
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4. The Use of Strontium in Bone Repair
Strontium is an element that has an approximate volume of distribution of 1l/kg. The Sr binding
capacity to human plasma proteins is low (~25%), but display high affinity for bone tissues. Studies
showed that Sr elimination is performed by the kidneys and gastrointestinal tract, but independent on
time or dose. The effective half-life is ~60 h. Sr plasma clearance is achieved at 12 mL/min (CV 22%),
while its renal clearance is achieved at 7 mL/min (CV 28%) [42].
It has been described that Sr is adsorbed on the surface of bone mineral, instead of replacing
Ca ions; this favors its rapid elimination. Nonetheless, Sr has a particular ability to cause catabolic
and anabolic effects during bone remodeling through the induction of prostaglandin synthesis and
expression of cyclooxygenase, which increases the differentiation to osteoblasts from mesenchymal
stem cells (MSCs). Peng et al. showed that Sr could increase bone osteoblastic differentiation in vivo,
and participate in the process of MSCs differentiation in vitro [43]. However, the mechanism by which
Sr affects the signaling pathways leading to osteogenic differentiation in human MSCs resulting in
bone formation is unknown [44].
According to in vivo experimental models, Sr is able induce anabolic events promoting bone
formation; however, further experimental and clinical analyses on the associated pathways are required
to clarify its effects at the molecular level [45]. Furthermore, in a postmenopausal osteoporosis animal
model, the long administration of Sr prevented the trabecular loss of bone induced by estrogen
deficiency, probably promoting bone formation by increasing bone mineral density and preventing
its resorption [45]. In this regard, experimental results showed that Sr administration increases the
number of osteoblasts, decreases the number of osteoclasts, and promotes matrix formation. Notably,
besides the effect on bone cells population and bone micro-architecture, Sr increases the mechanical
resistance of bone through changes in the properties of bone matrix [14,46].
Fernández-Murga et al. performed a global genomic study on the effect of different Sr compounds
and a calcium salt in pre-osteoblasts cultures, thus obtaining information on genes and the signaling
pathways involved in osteogenesis. Importantly, strontium induces the maturation process of
pre-osteoblasts after 21 days of treatment, nonetheless the most notable changes occurs immediately
at cellular level on gene expression and activation of signaling pathways related to osteogenic
events. Successive waves of changes in gene expression pattern occurs within 0–7 days, which
seems to be required to initiate the differentiation of pre-osteoblasts to a mineralizing phenotype.
The expression of many genes related to regulation of transcription, metabolic processes and
transport of molecules change in this first phase of the maturation process [46]. In this regard,
phosphorylation-dephosphorylation of proteins was shown to be the main biochemical event in this
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initial short time span; phosphorylation-dephosphorylation of proteins is well known to be involved in
the regulation of metabolic pathways as well as in other important cellular processes. For instance, Wnt
and NFAT signaling pathways were shown to be involved in the maturation of osteoblasts [47,48], as
both Wnt/β-catenin and NFAT pathways behaved as potent osteoprogenitors inducing gene expression
changes in short times. In contrast, cell cultures treated with strontium showed no activation of these
pathways at day 21. Hence, once confluence is reached, that is, when increased ALP activity and the
deposit of mineralized matrix are observed, the cells enter into the differentiation phase [46]. This
phase is characterized by an increase in the formation of bone matrix, which is associated to the change
in expression of 147 genes. In addition, cellular processes related to the energy state of the cell increases
remarkably in this second phase, namely carbohydrate metabolism (glucose and other carbohydrates)
including gluconeogenesis [46].
Overall, Sr is currently known to stimulate osteoblasts promoting osteogenesis both in vivo and
in vitro, while conversely, Sr down-modulates function in osteoclast preventing bone resorption [49,50].
The Sr anabolic effects involve Ca receptors leading to improve: preosteoblast replication, osteoblasts
differentiation, synthesis of collagen type I, and mineralization of bone matrix [18,51]. Sr replaces Ca
in the metabolism and functions of osteoblasts and also enhances osteogenesis inducing osteoblast
division while preventing osteoclast resorption. In addition, Sr enhances osteoblasts differentiation to
osteocytes [52]. In this regard, osteocytes modulate the function of both osteoblasts and osteoclasts,
thus displaying a role in the uncoupling of bone turnover by producing paracrine signals triggered by
the mechanical load [10,53–55].
Similarly to Ca, Sr is also absorbed in the intestine and finally distributed between three main
compartments, namely in plasma and extracellular fluids, soft tissues, and particularly in bones. Notably,
alteration of the Sr/Ca and Sr/P ratios have been linked to skeletal deformities [56]. Pasqualetti et al.
stated that bone deformities and other disorders occur at low Ca/Sr ratios, thus resulting in a slower Ca
uptake into bone tissue hence facilitating the replacement of Ca by other elements. The Sr usually acts
replacing Ca, as it displays physical and chemical similarity to Ca. Sr, once ingested, become present
in all body tissues; nonetheless, about 90% of it accumulates in the bones [57]. Sr is slowly excreted
by the body, and as suggested by Polak-Juszczak et al. this seems to be the cause of the high Sr and
low Ca concentration resulting in low Ca/Sr ratio values [56]. Similarly to Ca, phosphate (PO43−) is
also essential for proper body development by sustaining the skeletal system. P deficiency results in
reduced growth rates and bone mineralization, thus resulting in skeletal anomalies. Importantly, Sr
ingestion seems to cause a decreased assimilation of both Ca and P; hence, the values of Ca/Sr and
PO43−/Sr ratios are in some way related [56].
In several laboratories, the search of materials (as a vehicle for Sr) displaying low cellular toxicity,
even better showing synergistic activity in promoting regeneration of bone tissue, is highly active.
In this regard, a composite of Sr and Ca polyphosphate (CPP) was described showing excellent
mechanical properties with a steady release of Ca, PO43−, and Sr ions, which stimulates osteoblasts
growth in vitro [58]. In animal models (in vivo), the composite behaves similarly as in vitro, e.g., in
the canine femur, Sr-CPP composite promotes considerably bone formation and angiogenesis [59].
Similarly, Li et al. reported a composite consisting of Sr, hydroxyapatite (SrHA), and BisGMA, which
showed satisfactory bioactivity [60,61]. Hernandez et al. developed a cement based on SrHA and
poly(methyl methacrylate) intended to be used in minimally invasive surgeries, this composite showed
excellent bioactivity in vitro and thus, potential use in vivo. Notably, high biocompatibility is observed
in the above composites, which is characterized by low cytotoxicity and improved cell proliferation of
fibroblast cultures [62].
Therefore, Sr promotes cell proliferation and differentiation, as well as mineralization. Nonetheless,
Sr behavior seem to depend to the anion to which it is conjugated [46]; for example, it has been
used in combination with ranelate (SrRA) in bone regeneration therapy [63]. The salt has been
indicated in postmenopausal osteoporosis treatment showing effects also on cartilage and subchondral
bone. Preclinical studies performed indicate that SrRA inhibits subchondral bone resorption and
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promotes formation of the cartilage matrix in human chondrocytes, both in normal and osteoarthritic
conditions [63]. SrRA induces the maturation of osteoblastic cells and increases the synthesis of collagen
and non-collagen proteins. Regarding other effects of SrRA in bone formation, reports have shown that
it also improves the preosteoblastic cellular replication [64]. However, the use of SrRA is being reviewed
currently because of the increased incidence of cardiac failure events and thromboembolism [18],
while other important risks have also been reported, namely cutaneous adverse reactions, alterations
of consciousness, seizures, hepatitis, and cytopenia (European Medicines Agency, 2011). Therefore,
the unfavorable benefit-risk balance for Sr ranelate is clear; as consequence, marketing authorization
for pharmaceutical products (Protelos® and Osseor®) containing SrRA has been suspended by the
Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA).
Furthermore, a safety alert on severe allergic reactions has been issued for drugs containing Sr ranelate
(European Medicines Agency, 2011). In spite of that, others organic anions are being evaluated in order
to improve the bioavailability of Sr and to avoid most of the disadvantages associated with the ranelic
moiety [65].
Nonetheless, the development of bone replacement materials has continued to be an important
goal in medicine, mainly because of the disadvantages in the use of bone autografts. In this regard, the
intended use of Sr to this goal has not vanished and others composites have been tried, e.g., alginate
hydrogels prepared with arginine-glycine-modified aspartic acid (RGD) cross-linked with Sr and Zn
ions, and including Ca; Zn is required for alkaline phosphatase (ALP) activity. Although Ca and Sr
based hydrogels display different stabilities during storage, they have similar stiffness and support the
proliferation of osteoblast-like cells. Notably, the release of Sr from alginate gels is constant, sustained,
and biologically active. Sr induces positive regulation of phenotypic marker genes in osteoblasts:
RUNX2, collagen I (COL1A1) and bone sialoprotein (BSP), while ALP protein activity was maximal
in alginate gels containing Sr. The strategy may be extensive to combination with other systems
or to adaptation to applications in bone tissue engineering. It has been suggested that hydrogels
may be used as a reservoir for the slow-release of Sr leading to improve osteogenic activity and/or
differentiation [15]. Remarkably, studies showed that the effectiveness of Sr may be increased when in
combination with other ions [15,18].
During osteogenesis, multiple signaling pathways, including Vascular endothelial growth
factor (VEGF), runt-related transcription factor 2 (Runx2), osterix (Osx), bone morphogenic protein
(BMP), mitogen-activated protein kinase (MAPK), and the wingless-type MMTV integration site
(Wnt)/β-catenin pathways, regulate the proliferation and differentiation of osteoblasts, and hence are
involved in controlling bone formation. In addition, the increased expression of bone matrix proteins,
such as alkaline phosphatase (ALP), type I collagen (ColI), and osteopontin (OPN) also stimulate
mineralization and bone formation [66]. Osteoblasts, besides regulates bone formation, also control
bone resorption by modulating osteoclastogenesis via osteoprotegerin (OPG)/receptor activator of
nuclear factor-κB and ligand (RANKL)/receptor activator of nuclear factor-κB (RANK) system [66,67].
Vascular endothelial growth factor (VEGF) is involved in angiogenesis and vascular
homeostasis [68] and plays an essential role for regulating angiogenesis, endothelial cell function,
and hence, signaling maturation of osteoblasts, ossification, and bone turnover. [69]. The angiogenic
process accompanies bone regeneration acting as a limiting factor for the healing process [70].
Salinas et al. [71] showed a synergistic effect of VEGF adsorbed on silicon substituted hydroxyapatite
scaffolds, resulting in more ossification, larger trabeculae and higher degree in angiogenesis [71].
Interestingly, incorporation of Sr in a fluorapatite glass-ceramics system leads to a highly ordered
microstructure, increased solubility, and sustained Sr release, demonstrating that the in situ delivery
of key elements is an attractive strategy to promote both angiogenesis and osteogenesis [10,72]. The
fluorapatite-based glass composite sustained the release of Sr in vitro and in vivo, where the rate
of mineral apposition is higher than the Sr undoped composite. Therefore, the efficiency of Sr in
promoting osteoblastic activity is clear [10].
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Among a series of GFs used in exogenous delivery strategies in bone repair, the bone morphogenetic
proteins (such as BMP-2) are well known that promote osteoblastic differentiation of MSCs as well
as the regeneration of bone at early phase of formation [73]. BMP-2 in conjunction with biochemical
factors (chemical compounds, bioactive cytokines, and drugs) is known to synergistically promote
osteogenesis, thus leading to bone regeneration under physiological microenvironment [74]. In example,
some vitamins maintain body Ca and PO43- balance, while the drug dexamethasone (Dex) promotes
osteogenic differentiation of MSCs in vitro [75,76]. Hence, a synergistic effect of BMP-2 and vitamin
D3 in osteogenic differentiation of adipose derived stem cells (ADSCs) has been observed in vitro;
a high dose of vitamin D3 upregulates ALP expression and mineralization of ADSCs. Additionally,
studies have showed a controlled and sustained release of BMP-2 and Dex using engineered delivery
platforms activating bone regenerative processes [73].
BMP-2 is known to induce or promote the expression of RUNX2; a transcription factor essential for
osteoblast differentiation and bone formation [77]. Nonetheless, ALP, COL-1, and osteocalcin are also
essential in osteoblast differentiation, thus also considered as molecular markers in bone formation [78].
BMP-2 regulates osteoblast differentiation by stimulating osteoblast-related transcription factors,
such as RUNX2 and SMAD1, while the closely-related protein, SMAD5 mediates the responses to
BMP-2 [73,76]. Bone morphogenetic proteins (BMP) are members of the TGFβ superfamily. These
proteins have diverse functions in multiple developmental processes such as in embryogenesis,
organogenesis, bone formation, cell proliferation, and stem cell differentiation [73].
Bone marrow MSC cultures, when exposed to Sr, displays a significant increase in the expression
of the master gene, Runx2, and bone sialoprotein (BSP), which are associated to the increase of
colony-forming unit osteoblasts. Interestingly, the Sr mediated activation of gene expression varies
with differentiation stage of MSC; namely, Runx2 and BSP in bone marrow MSC, Runx2 and osteocalcin
in preosteoblasts, and BSP and osteocalcin in mature osteoblasts [55].
5. Role of Folic Acid and Vitamins B6 and B12 in Bone Regeneration
Folate (FO) is a group of chemically complex substances of which the main role is to provide
methyl groups in biosynthetic pathways. The human body is unable to synthesize FO; it is obtained
from foods, and nowadays also in the form of dietary supplements. FO is essential at all ages in human
life, from early development in the uterus to adulthood [79].
Biochemically, FO is a coenzyme that transfers carbon units necessary for the formation of
deoxythymidylate used in the synthesis of purine and others methylation reactions. Therefore, folate is
essential for cell division, embryonic and fetal development, and in the maintenance of cardiovascular
and neurological functions. FO is produced by green plants, especially leafy vegetables, and some
microorganisms, and it is found as a derivative of the reduced form of tetrahydrofolate (THF). Ingested
FO becomes functional after intestinal absorption, distribution, transport into the cells, and biochemical
modification. The lack of nutritional FO supplementation has been related to chronic pathologies
such as cardiovascular disease, cancer, and cognitive dysfunction. Importantly, deficient nutritional
status in maternal FO (Folic acid and FO derive from the aqueous soluble vitamin B9) is related to
defects in the neural tube in offspring [79,80]. Therefore, folic acid supplementation during pregnancy
is recommended by reproductive health epidemiological studies in different groups of women [81].
Nowadays, the consumption of probiotics is a new alternative to the supplementation of FO, e.g.,
strains of Bifidobacterium producing FO have been tested in humans and animals showing increasing
levels of FO in plasma [82].
The effect of folic acid on bone turnover and bone metabolism has been evaluated [83,84].
Published results showed that folic acid supplementation does have beneficial effects on bone health
status [85]. The effect of folic acid on bone metabolism and its turnover has been evaluated during
pregnancy [27,85]. Results showed that pregnant women with daily folic acid (1 mg) supplementation
until the birth time display significant higher plasma levels in OPG concentration and lower in
sRANKL concentration than pregnant women with folic acid supplementation up to the second
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trimester, consequently low rates in bone resorption is implied [85]. Importantly, better results are
obtained when higher folic acid dose (5 mg/day) is administered, i.e., the sRANKL/OPG ratio further
decreases [27].
Inflammatory cytokines (IL-1, TNF, and M-CSF), which are released when osteoclastic bone is
lost, stimulate RANKL production in osteoblast precursors and/or development of osteoblasts [86]. In
contrast, these cytokines decrease OPG production through up-regulation of the RANK receptor in
osteoclast precursors, thus increasing their sensitivity to normal RANKL concentrations [27,87]. In this
regard, studies showed that TNFα in serum decreases significantly during the administration of a high
dose of folic acid. The TNFα decrease correlates with the decrease in sRANKL levels. Importantly,
TNFα promotes osteoclastogenesis via RANKL system, i.e., by up-regulation of RANKL mRNA
expression [88]. Therefore, in pregnant women folic acid supplementation in high dose decrease bone
resorptive biomarkers by increasing OPG level and decreasing sRANKL and TNFα levels [27].
B-vitamins are a group of soluble vitamins that are cofactors of some of the enzymes involved
in the metabolic pathways of carbohydrates, fats, and proteins; due to their promising properties,
researchers have studied the advantages of their use in the clinical field, such as boosting the immune
system [89]. B-vitamins are excellent adjuvants to achieve regeneration in several types of tissue.
According to Fernández-Villa et al. folic acid derivatives are considered one of the most encouraging
derivatives because they fulfill the requirements for their application in clinical use. It has been shown
that these derivatives promote regenerative processes in a wide range of tissues and organs; further
folic acid derivatives show a long lifespan under physiological conditions. This is the greatest limitation
in regenerative therapies; e.g., when using growth factors or other recombinant proteins [90].
B-vitamin has also been linked to osteogenesis. An experimental study from Herman et al. showed
a strong stimulation of human osteoclasts by the amino acid homocysteine (HCY) [91]. Other potential
effects of HCY-related osteoporosis are reduced osteoblast activity [92] and disturbed extracellular
collagen cross-linking [93]. It was proposed that the elevated HCY concentration in vivo is caused
mainly by deficiencies in FO, vitamin B12 and B6, as they are directly involved in degradation of HCY.
In a large series of experiments using cell cultures, Herrman et al. demonstrated the important role of
FO and these B-vitamins in bone metabolism, namely FO, vitamin B12, and vitamin B6 stimulated
osteoclast activity by accumulation of HCY [94]. In contrast, in preosteoblastic bone marrow cells,
vitamin B12 increases alkaline phosphatase activity in a concentration-dependent way [91].
Likewise, folic acid and FO are important molecules in bone health; vitamin B9 derive from both
molecules. The most prominent role of vitamin B9 is detoxification of HCY related to inflammation
and to increased risk of fractures. Studies performed in developed countries showed that women
(during menopause) experience a diminished ability to manage homocysteine adequately and that
supplementation with folic acid improves the processing of homocysteine [95]. Nonetheless, this is not
yet recognized as a universal [96].
Hyperhomocysteinemia seems to have a potential role in the development of osteoporosis. HCY
is the aminoacid produced in methionine catabolism. Interestingly, serum concentration of HCY shows
an inverse relationship with vitamin B12 and folic acid [96]. HCY metabolism is related therefore to
methionine concentration, expression of enzymes, concentrations of cofactors (vitamin B6 and B12), and
FO (tetrahydrofolate production). Therefore, a deficiency in enzyme activity or the absence of cofactors
may cause accumulation of HCY in cell cytoplasm, but also in blood plasma [97,98]. Importantly,
studies have shown an association between high blood plasma HCY levels and osteoporotic fractures
in elderly women and men [99]. The proposal that HCY plays a role in bone metabolism is supported
by studies examining the relationship between a polymorphism in the methylene tetrahydrofolate
reductase gene (MTHFR) and bone mineral density (BMD). However, the exact relationship between
the level of HCY in plasma and BMD is uncertain. Methylation of HCY leads to form methionine
in a reaction catalyzed by methionine synthase [100]. Methyl-tetrahydrofolate behaves as the donor
of the methyl groups using vitamin B12 as a cofactor. Methyl-tetrahydrofolate is synthesized from
folic acid, in a route where methylenetetrahydrofolate-reductase (MTHFR) participates using FAD
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(flavin-adenine-dinucleotide) as a cofactor. Therefore, four vitamins (folic acid, vitamin B6, vitamin
B12, and riboflavin) participate in the metabolic reactions leading to decrease HCY levels. Deficiencies
in these vitamins increase homocysteinemia, this in turn impact in bone mineral density [100].
A relationship between homocysteine levels and the incidence of fractures seems to exist in
individuals [98,101]. However, no relationship has been found between homocysteine levels in
plasma and density in bone mineral [101]. Nonetheless, other studies have shown that folic acid
and vitamin B12 deficiency is specifically associated with a decrease in BMD and a high incidence of
fractures [102,103]. Since folic acid, vitamin B12, and homocysteine are metabolically related, their
specific influence in skeletal homeostasis becomes difficult to determine; however, when analyzed
in conjunction, a statistically significant association is observed in the concentration of folic acid and
vitamin B12 with BMD [100].
BMD and bone mineral content are known to be influenced by Vitamin B12, Ca, and vitamin
D. In this regard, studies in vitro show that vitamin B12 does have a significant effect on osteoblasts
proliferation, e.g., vitamin B12 increases alkaline phosphatase activity in osteoclastic cells. A minute
amount of vitamin B12 is necessary to observe a positive effect on osteoblasts proliferation. In elderly
patients, Dhonukshe-Rutten et al. found a relationship between vitamin B12, BMD and bone mineral
content [104]. Therefore, as vitamin B12 seems to be related to bone health, the treatment of vitamin
B12 deficiency may help to prevent osteoporosis. Additional studies in elderly women showed an
association between vitamin B12 levels, its content in bone mineral, and BMD [104]. Therefore, the
decrease or increase in vitamin B12 levels seems to be related to BMD, and thus to the susceptibility or
not to bone fractures, respectively. In agreement, the observed prevalence ratio in osteoporosis was
higher in groups with deficient to marginal vitamin B12 than those with normal levels. Studies suggest
that clinical deficiency in vitamin B12 may be associated with poor functional maturation of osteoblasts
and thus bone formation and resorption, respectively [91]. Vitamin B12 participates as a cofactor in the
transformation of homocysteine to methionine; however, the mechanism by which bone density is
affected is not fully understood [96].
6. Synthesis and Properties of SrFO
Currently, the development of new osteogenic therapies is on clinical demand, namely in the
treatment of osteoporosis and other bone diseases. The therapy based on Sr seems promising;
nonetheless, any formulation should provide an effective and consistent way to deliver Sr ions with
low or absence of secondary pharmacological effects. In this regard, Rojo et al. [18] developed a new
strategy for Sr delivery based on FO as the carrier [18]. Experimental results showed the improvement
in the regenerative capacity of skeletal tissues; thus evidencing a high efficiency of Sr as the active
compound. Certainly, FO (the anionic form of folic acid) is a promising alternative as a Sr carrier in
composites [18]. Additionally, the incorporation of B vitamins (folates) may contribute improving the
metabolism and other processes in cells involved in bone regeneration [90].
Ca and SrFO complexes have been obtained and characterized physicochemically, and their
bioactive properties in osteoporosis treatment have been evaluated (Figure 2) [18,58].
Sr folate (SrFO) shows low toxicity in vitro in human osteoblasts cultures and human mesenchymal
Stem Cells, while inducing a significant expression of alkaline phosphatase (ALP) when compared to
its Ca analogue (Figure 3). Studies suggest that SrFO could certainly display important therapeutic
properties. Nonetheless, detailed analysis in SrFO physicochemical properties as well as the biological
interaction with osteoblast and human stem cells have been conducted (Figure 4).
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cultured for four days in osteogenic differentiation medium (left), MEM medium (center) and MEM +
Strontium Folate (SrFO) (left). Arrows indicate deposits of calcified extracellular matrix. Scale bar =
100 µm [105].
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These studies would allow to state confidently its effect in bone regeneration, and consequently,
its potential application in medical therapies, e.g., in chronic-degenerative bone diseases. Bioassays of
SrFO and other chosen materials included in ceramic composites has been the subject of our laboratory,
with the aim to develop a superior osteogenic scaffold behaving in a dual way, i.e., remodeling
bone tissue by stimulating osteogenesis (cell proliferation) from dental pulp and by inhibiting bone
resorption induced by osteolysis [18,105].
7. SrFO Loaded Biohybrid Scaffold Seeded with Dental Pulp Stem Cells as a New
Composite System
7.1. Scaffolds Preparation Procedures and Characterization Techniques
Increasing interest exist in biodegradable ceramic scaffolds for bone tissue engineering with the
ability to deliver active molecules favoring bone formation. Denry et al. showed the action in vivo of
strontium-containing glass-ceramic scaffolds, where Sr was successfully incorporated in the newly
formed bone, thus increasing significantly the mineral apposition rate evidencing the benefits of in
situ release of Sr [10]. Similarly, Tian et al. demonstrated the biocompatibility, osteogenesis (in vivo),
and degradability of porous Sr-doped Ca polyphosphate scaffolds in bone substitute applications.
Yang et al. [44] synthesized collagen-Sr-HA scaffold to evaluate the in vivo effects of Sr on bone
formation [44]. Sr based systems are usually designed to serve as models for the manufacture of
scaffolds. To date, only two studies do exist, which are the watersheds in the development of graft
substitutes. Recently, Xu et al. tested titanium implants covered with Sr ions chelated with folic acid.
The SrFO derivative was stable for long time, while minimal Sr ions release to body fluids. This
device promoted the in vitro osteogenic differentiation of MSCs upon implantation. More recently,
Martín-del-Campo et al. [16] prepared bioactive porous scaffolds by free radical polymerization
of polyethylene glycol methacrylate in the presence of β-tricalcium phosphate (TCP) and SrFO as
bioactive compounds (Figure 5) [16]. Roy and Bose tested in vitro the effects of Sr doping in β-TCP on
differentiation of mononuclear cells into osteoclast-like cells and its resorptive activity, osteoclast-like cell
formation, adhesion and resorption. Hence, substrate chemistry may control osteoclast differentiation
and resorptive activity. Furthermore, it may be used for the design of TCP-based resorbable bone
substitutes with controlled degradation and osteoclast-like cell formation activity [106].Molecules 2019, 24, x FOR PEER REVIEW 12 of 21 
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scaffolds are typically porous with a homogeneous structure and consistent cylindrical shape. Pores
are homogeneously distributed displaying interconnected macropores (>100 µm) and micropores
(<10 µm) [16]. The above are in agreement with previous studies, thus demonstrating that the
presence of Sr in 3D biohybrid scaffolds does not influence the macro- and meso-porous structure in
scaffolds. In addition, they provide proper dissolutions rates for Ca and Sr ions and exhibit an excellent
microenvironment for cell viability, differentiation and osteogenic activity [19,108,109]. The mapping
of elements in scaffolds were performed by energy-dispersive X-ray spectroscopy (EDS) in a scanning
electron microscope (SEM) in order to determine the presence of TCP particles and SrFO (Ca and Sr
elements respectively) and its dispersion in the matrix.
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Figure 6. β-tricalcium phosphate (TCP) and TCP/SrFO porous scaffolds obtained by free radical
polymerization and lyophilization and surface analysis by scanning electron microscope (SEM) and
energy-dispersive X-ray spectroscopy (EDS) spectroscopy [107].
The success of polymerization reaction, and absence of free monomers in TCP and TCP/Sr
scaffolds were confirmed by Fourier transform infrared spectroscopy (ATR-FTIR) by the absence of
the characteristic vinyl bands (ν) as C=C at 1637 cm−1. The presence of a strong vibrating band at
1726 cm−1 corresponding to the carbonyl ester of the ceramic component was also discriminated from
bands associated to phosphate groups (high and low intensity) observed in the region of 1000 to
500 cm−1 (Figure 7) [18].Molecules 2019, 24, x FOR PEER REVIEW 13 of 21 
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Figure 7. Surface analysis by FTIR-ATR spectroscopy of TCP and TCP/Sr scaffolds. Figure adapted
from Martín-del-Campo et al. [16] with permission from the Royal society for Chemistry.
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7.2. DPSC Viability on Scaffolds
Studies suggest that incorporation of Sr ions in bone substitutes constitutes a safe and effective
way to stimulate proliferation and differentiation of bone MSCs, osteoblasts, and periodontal ligament
cells in vivo [19–21]. Recently, Martín-del-Campo et al. demonstrated that incorporation of SrFO into
bio-hybrid scaffolds enhances the osteogenic differentiation of HDPSCs. That is, by performing cell
culture and characterization of DPSCs, the HDPSCs phenotype and osteogenic profile were confirmed
by immunoassays and the expression level of three osteogenic markers (RUNX-2, osteopontin, and
osteocalcin), representative of middle and late stages of osteogenic differentiation, were determined
histochemically (Figure 8) [16].
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Figure 8. Differentiation of HDPSCs. Expression of RUNX-2, OPN, and OCN at days 14 and 21, (40×
magnification). Scale bar 100 µm. Reproduced from Martín-del-Campo et al. [16], with permission
from The Royal Society of Chemistry.
Cell viability and proliferation in composite scaffolds w re confirmed, showing a large increase
in cell population in TCP/SrFO group. After day s ven, H & E viability assay showed a higher cell
number in TCP/SrFO scaffolds than the TCP group (Figure 9). Xu et al. [17] confirmed that the high
stability of Sr substrates improves cell proliferation in a long term resulting in a remarkably effect on
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density of the newly bone formed is higher in SrFO group compared with that in TCP (Figure 11) 
suggesting that Sr promoted the formation of new bone. Yang et al., [44] showed that in HA and Sr-
containing scaffolds, the Ca phosphate based scaffold induces the formation of only some mature 
collagen fibers at the edges of the bone defect, while Sr-containing scaffold induces the formation of 
mature and remodeled bone at the boundary and in the central bone defect resulting in a relatively 
high bone density [44]. 
Figure 9. H & E staining on sliced TCP/SrFO (A1) and TCP (B1) scaffolds and nuclei staining
(A2 and B2 respectively) of HDPSCs used for the viability quantification. Figure adapted from
Martín-del-Campo et al. [16] with permission from The Royal Society of Chemistry. Stars show
significant differences throughout days * (p < 0.0049) *** (p < 0.0001) **** (p < 0.0001).
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7.3. Rat Calvarial Defect Model and Implantation of the Scaffold
Martín-del Campo et al. implemented a calvarial defect biomodel to perform the implantation of
SrFO/TCP scaffolds by filling completely the defective area (Figure 10).
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H & E staining of implants in the bio-model evidenced the formation of mature bone tissue
in Sr-systems, displaying a highly organized laminar tissue and the absence of scaffolds remnants.
Alizarin red stain when assayed at specific time intervals post-implantation displays the stages of
mineralization of the newly formed tissue. In TCP/SrFO scaffolds implants a line like structures is
observed indicating the start of mineralization and Ca organization, while osteocytes were observed
in matrices indicating on site calcification. Von Kossa stain assay showed the start in calcification,
after week 20th, the TCP/SrFO group shows the presence of organized mineralized tissue with the
appearance of complete and mature bone. Mineralization is observed through cells and lamellar Ca
deposits [16]. Xu et al. confirmed that Sr folic acid derivate may significantly enhance the ALP activity
of MSCs in a short-time, and sustain an upregulated ALP activity for longer time. The mineralization
of MSCs, as a late stage marker in osteogenic differentiation, demonstrates that Sr folic acid substrates
promote MSCs osteogenic differentiation [17].
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